Dossier assessment

Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) – Benefit assessment according to § 35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-113
Last updated

Report documents

  1. Extract of dossier assessment

    Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) – Benefit assessment according to § 35a Social Code Book V

    published on
    Document type
    PDF document, 434 kB, EN, not accessible
  2. Dossier assessment

    Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) – Benefit assessment according to § 35a Social Code Book V

    published on
    Document type
    PDF document, 854 kB, DE, not accessible

Dossier assessment

Indication:

Children aged 4 weeks to 11 years and weighing at least 3 kg with COVID-19 and pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A22-113
Commission
Commission awarded on 17.10.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-04
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-38
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) – Benefit assessment according to § 35a Social Code Book V

    Project no.
    A22-112
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form